Vivo Capital LLC acquired a new position in shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,927,710 shares of the company’s stock, valued at approximately $7,981,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. Affinity Asset Advisors LLC acquired a new position in shares of OnKure Therapeutics in the 1st quarter worth approximately $998,000. ADAR1 Capital Management LLC raised its position in shares of OnKure Therapeutics by 140.1% during the 1st quarter. ADAR1 Capital Management LLC now owns 2,434,941 shares of the company’s stock valued at $10,081,000 after acquiring an additional 1,420,783 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in shares of OnKure Therapeutics during the 4th quarter valued at approximately $58,000. XTX Topco Ltd bought a new position in OnKure Therapeutics during the fourth quarter worth $52,000. Finally, Kotler Kevin acquired a new position in OnKure Therapeutics in the fourth quarter worth $573,000. Institutional investors own 90.98% of the company’s stock.
OnKure Therapeutics Stock Up 1.3%
Shares of NASDAQ OKUR opened at $4.00 on Friday. The stock’s fifty day simple moving average is $4.27 and its 200 day simple moving average is $3.80. The stock has a market capitalization of $161.58 million, a price-to-earnings ratio of -0.92 and a beta of 0.27. OnKure Therapeutics, Inc. has a 52-week low of $1.91 and a 52-week high of $5.38.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on OKUR shares. JonesTrading downgraded shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Wall Street Zen raised shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Weiss Ratings cut shares of OnKure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Finally, HC Wainwright decreased their target price on OnKure Therapeutics to $21.00 and set a “buy” rating for the company in a research note on Monday, July 20th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, OnKure Therapeutics has an average rating of “Hold” and an average price target of $21.00.
Check Out Our Latest Stock Analysis on OKUR
OnKure Therapeutics Company Profile
OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.
The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.
Read More
- Five stocks we like better than OnKure Therapeutics
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Want to see what other hedge funds are holding OKUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OnKure Therapeutics, Inc. (NASDAQ:OKUR – Free Report).
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
